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Solitary fibrous tumor (SFT) and hemangiopericytoma (HPC) were considered, since their
firsts description in the literature, as separate entities. The World Health Organization (WHO)
classification of soft tissue tumors in 2013 declared the term HPC obsolete, and considered
these lesions as features of the extrapleural SFT category. Herein we present a rare case of
SFT originating from the great omentum. A 68 years old woman was admitted to our 
hospital with acute abdominal pain. Computed tomography revealed a 142 x 102 x 100 mm
solid mass located in the pelvis, that simulated an adnexal lesion. An explorative laparotomy
was performed, and a mass of the great omentum with a significant vascular pedicle arising
from a branch of the left gastroepiploic artery was revealed. The tumor was completely
resected. Microscopically it was composed by non-organized and spindle-shaped cells
exhibiting atypical nuclei, arranged in short fascicles, and was diagnosed as. An extensive
search was conducted in public scientific databases for published articles on the topic, with
the aim to comprehensively describe the demographic, clinical, pathological and prognostic
features of SFT; 60 previous cases have been identified and reviewed. 
Key words: omentum, solitary fibrous tumor, hemangiopericytoma, mesenchymal tumor,
SFT/HPC
INTRODUCTION
The greater omentum is an anterior vascular fatty apron-like fold supporting
the abdominal viscera protecting them against tumors and infections. The most
common malignancies of the greater omentum are due to carcinomatosis, 
secondary to peritoneal or hematogenous spread of digestive (colorectal, 
stomach, pancreas) or ovarian tumors. Solitary fibrous tumor (SFT) is a 
mesenchymal neoplasm that generally grows in the pleura, and occasionally in
other body districts, including subcutaneous tissue, head and neck (especially
the orbit), thoracic wall, mediastinum, pericardium, and retroperitoneum. Other
reported locations include the meninges, spinal cord, periosteum, as well as
organs like the salivary glands, lung, thyroid, liver, gastro-intestinal tract, 
adrenals, urinary bladder, prostate, spermatic cord and testes, and can be both
benign and malignant (1). Only a few SFT cases involving the omentum have
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been reported in the scientific literature to date. We
herein report a rare case of omental SFT. 
CASE REPORT
A 68 years old Caucasian woman, with no 
remarkable medical history, was referred to the
University Hospital of Udine, Italy, for abdominal pain
lasting 48 hours, with no further symptoms such as
fever, stomach-ache, nausea or vomiting. Clinical 
examination showed a plethoric and soft abdomen,
with no remarkable signs, but with a tender palpable
mass moderately painful in the right lower abdominal
quadrant.  Laboratory data showed high white blood cell
count (13200/μL) and C-reactive protein (41 mg/L). A
contrast-enhanced computed tomography (CECT) scan
of the abdomen and pelvis was performed, and showed
a 142x102x100 mm mass occupying large part of the
lower abdominal cavity, compressing the bladder and
uterus, and resembling an adnexal lesion (figures 1 and
2). The mass showed low signal density, with regular and
well defined borders, and after contrast injection, it was
clearly enhanced, showing a mixed pattern of well 
vascularized and apparently necrotic areas. The mass
drained into a dilated omental venous plexus. Neither
vascular thrombosis, nor spread to adjacent organs
were detected.  
An explorative laparotomy was performed, and a
large tumor originating from the greater omentum
was found. The lesion, partly surrounded by omentum,
was tightly adherent with the inferior curve of the
stomach. A dilated artery apparently originating
from the left gastroepiploic artery, which seemed to
feed the tumor, and an abundant and expanded
blood vessel network, were present along the 
surface of the mass, leading to a 100 ml blood loss
during excision. The lesion was successfully isolated
and excised in toto with no technical difficulties and
without resection of adjacent organs. The post-
operative course of the patient was uneventful, and
she was discharged five days after surgery. The
patient gave her informed consent for all the medical
procedures, and for the use of her anonymous 
clinical data for research purposes. 
At gross pathological examination, the tumor 
measured 140x95x80mm in size, and was well-
circumscribed, solid, multilobulated, beige-pink in
colour, with a 55mm haemorrhagic area (figure 3).
Microscopically, it was composed of non-organized
spindle-shaped cells, divided by branching vessels
with intravascular thrombosis and multiple ischemic
areas. No remarkable atypia was detected. Few
mitotic figures (<3/10 high power field) were 
present. No immunohistochemical staining for EMA,
CD99, cytokeratine, desmin, CD10, CD117 and 
DOG-1 was found, while staining positivity for CD34,
bcl-2 and smooth muscle actin (SMA) was detected,
leading to the diagnosis of a SFT. The patient was
regularly followed-up with periodic imaging for the
last four years, and no recurrences occurred. 
Figure 1 - Abdominal computed tomography scan showing the pelvic omental SFT
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DISCUSSION 
The first description of SFT dates back in 1931 (2) as
a neoplasm originating from the pleura. The pleural
sheets are most commonly affected by malignant
mesothelioma, and represent the most common site of
occurrence of SFT (3). It has been, indeed, hypothesized
that SFT originates from sub-mesothelial mesenchymal
cells (4). Extrapleural sites of origin, like the peritoneum,
mediastinum, limbs, orbits and parotid glands have been
subsequently described, and are less frequent but 
associated with particular clinico-pathological implica-
tions and higher risk of malignancy. Hemangio-
pericytoma (HPC), on the other hand, was first
described by Stout and Murray in 1942 as a rare tumor
of Zimmermann’s pericytes (5). Although this tumor
can arise anywhere, the muscles of the lower limbs, 
the pelvic fossa, and the retroperitoneum are the 
predominant sites of origin described. The fourth 
edition of the World Health Organization (WHO)
Classification of Tumours of Soft Tissue and Bone 
published in February 2013 (6) erased these two 
entities, which are since then considered a unique
tumor occurring commonly at all the sites of origin
mentioned. Nevertheless, some pathologists continue
to maintain the old classification, despite the morpho-
logical and pathological features of the lesions are
indeed related. 
To date, only a few cases of SFT have been reported.
We conducted an extensive electronic article search on
PubMed and Scopus databases with the aim to identify
published reports on SFT. The following keywords were
used for research: “solitary fibrous tumor”, “solitary
fibrous tumour”, “hemangiopericytoma”, ‘’haemangio-
pericytoma‘’, “great omentum”, “greater omentum”,
“omentum” and ‘’omental’’ both as single terms or in
combination. All the results were screened by two
researchers (CB, AU), regardless of the reporting 
language, for cases with demographic, clinical and
pathological information available. Subsequently, a
cross-check of the reference lists of selected articles
was performed to find any missed papers. 
This way, there were 60 cases identified in 57 articles
(7-63), a number consistently higher than those 
reported in previous reviews. The main demographic,
clinical, pathological and immunohistochemical data of
the cases enrolled are summarized in table 1. SFT did
not show any gender predilection. Most cases occured
during the 5th and 6th decades of life, and no 
environmental factors have been identified to increase
the risk of SFT (64). The mean age in the whole cohort
was 51 (range 24-92) years, and 29 patients were males
(51%, table 1). In five patients the age or gender were
not mentioned.
Patients with intra-abdominal SFT most commonly
had a relatively indolent behaviour, and were often
affected by a palpable abdominal mass or abdominal
pain, vomiting and weight loss (65). Information about
Figure 2 - Abdominal computed tomography scan showing a
hypervascularized and heterogeneous solid tumor in the pelvis,
with vascular feeding from the left gastroepiploic vessels
Figure 3 -  Gross appearance of the resected SFT: 
a well-encapsulated pink and smooth solid mass, 
measuring approximately 14 cm
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the personal clinical history was available in 52 cases;
only in 9 (15%) cases the patients were totally 
asymptomatic, while abdominal or pelvic pain (41%), 
abdominal-pelvic mass (21%) and vomiting (7%) 
were the clinical manifestations most frequently
encountered (table 1). The clinical symptoms were
Author (citation) Year Age/Gender Symptoms/signs IHC
Stout et al. (7)  AUTOPSY 1943 92/M abdominal mass NA
Stout et al. (8) 1963 63/M abdominal mass with pain NA
Stout et al. (8) 1963 57/F NA NA
Stout et al. (8) 1963 64/M abdominal pain, nausea NA
Lortat-Jacob et al. (9) 1966 NA/M abdominal mass, constipation NA
Goldberg et al. (10) 1968 30/F abdomnial pain NA
Meyer et al. (11) 1976 55/M abdominal mass, constipation Reticulin+
Krejczy et al. (12) 1978 NA/NA NA NA
Alusik et al. (13) 1978 NA/NA NA NA
Harder et al. (14) 1983 37/M abdominal pain NA
Karabanov and Safiullin (15) 1989 61/F abdominal mass NA
Imachi et al. (16) 1990 62/F abdominal distension with pain NA
Schwartz et al. (17) 1991 40/M abdominal mass with pain, wheight loss NA
Cajano et al. (18) 1995 NA/NA NA NA
Bertolotto et al. (19) 1996 33/F No NA
Pozharliev et al. (20) 1997 45/M abdomnial pain, atshenia NA
Watanabe et al. (21) 1998 66/M No CD34+
Borgmann et al. (22) 1999 32/F abdominal mass NA
Borgmann et al. (22) 1999 57/F abdominal mass NA
Rao et al. (23) 2000 67/M abdominal lump NA
Kaneko et al. (24) 2003 70/F lower abdominal mass grown over the past year NA
Bovino et al.  (25) 2003 46/F severe upper abdominal pain, nausea, vomiting vimentin+, keratin-,
LCA-, S100-
Patriti et al. (26) 2004 24/M lower abdominal pain, diarrhea, fever CD34+, bcl-2+, 
pancytokeratin-
Ahmad et al. (27) 2004 74/F abdominal distension, weight loss, diarrhea, CD34+, vimentin+,
vomiting SMA+, desmin+, Factor VIII+,
S100-, cytokeratin-, CEA-
Crusco et al. (28) 2005 28/M acute pain in the lower left quadrant NA
Kim et al. (29) 2005 60/F NA NA
Piazza et al. (30) 2005 28/F acute pelvic pain NA
Sukharev et al. (31)  2006 NA/NA NA NA
Shiba et al. (32) 2007 41/F epigastric pain CD34+, factor XIIIa+, 
HLA-DR+
Slupski et al.  (33) 2007 61/M left lumbar pain NA
Salem et al. (34) 2008 60/M periumbilical pain, weight loss CD34+, CD99+, SMA-,
desmin-, S100-, C-kit - 
Chatterjee et al. (35) 2008 41/M NA CD34+
Peixoto Callejo (36) 2009 44/M abdominal tumour, anorexia, weight loss CD34+, CD117-
Mosquera and Fletcher (37) 2009 40/M lower abdominal pain CD34+, p16+, p53+, EMA-,
AE1/AE3-
Prakash et al.  (38) 2009 45/F lower abdominal pain NA
Kucuk et al. (39) 2009 70/M abdominal diffuse pain, nause, vomiting CD34+, vimentin+
Table 1 - Main demographic, clinical and immunohistochemical findings of SFT of the greater omentum 
as depicted in the current literature
Author (citation) Year Age/Gender Symptoms/signs IHC
Maassarani et al. (40) 2010 63/F NA NA
Morris-Stiff et al. (41) 2011 68/M No CD34+
Garbin et al. (42) 2011 27/F No NA
Furukawa et al (43) (AUTOPSY) 2012 69/M NA CD34+, vimentin+, SMA+,
type IV collagen+, S-100-,
cytokeratin-
Uemura et al. (44) 2012 48/M painless mass in the left inguinoscrotal area CD34+, CD99+, desmin-,
S100-, SMA-, bcl-2-
Zong et al. (45) 2012 29/M epigastric discomfort and compression, CD34+, CD99-, bcl-2+,




Virgilio et al. (46) 2014 74/M No CD34+, bcl-2+
Becker et al. (47) 2014 41/F distended abdomen, early satiety, CD34 +, bcl-2+,
postprandial vomiting vimentin+
Osawa et al. (48) 2014 32/F irregular vaginal bleeding CD34+, bcl-2 +, SMA+, S-100-,
c-kit -
Harada et al. (49) 2014 62/F vaginal discharge CD34+, CD99+, bcl-2+, vimentin+,
p16+, p53+, CD10+, PR+, S100+,
c-kit+, EMA+, cytokeratin
AE1/AE3+, SMA-, desmin-, D2-40 -, 
calretinin-, ER-, CD31-
Sato et al. (50) 2014 85/F hypogastric mass NA
Senda et al. (51) 2014 45/F No CD34+, bcl-2+, c-kit+, 
S-100-, desmin-
Cazejust et al. (52) 2015 68/F left subcostal pain CD34+, bcl-2+, C-kit -, DOG1-
Urabe et al.  (53) 2015 52/M No CD34+, STAT6+, C-kit-, S100 -,
desmin -, 1A4-
Moszynski et al.  (54) 2016 29/F pelvic pain, loss of appetite, bloating CD34+
Jaber et al. (55) 2016 69/F lower abdomen pain vimentin+, CD34+, CD31+,
reticulin+, keratin -, EMA- 
Archid et al. (56) 2016 25/M lower abdominal pain CD 34+, CD99+, AE1/3-,
desmin-, CD31-, CD117-,
DOG1 -, S100- MIB1 5%
Rodriguez Tarrega et al. (57) 2016 34/F No CD34+, CD99+, beta
catenin+, SMA-, desmin-, 
kit-, DOG1-
Michiura et al. (58) 2016 36/M cough, abdominal mass CD34+, bcl-2+, CD99+, p53+,
S-100-, a-SMA-, c-kit-, desmin-
Bushira S.S. (59) 2017 45/M abdominal pain and swelling CD34+, factor-IIIa+, HLA-DR+
Yousefi et al. (60) 2018 24/F lower abdominal pain CD34+, CD99+, cytokeratin-,
LCA-, CD117-, Synaptophysine-,
Calretinine-,  Inhibin-
Vasdeki et al. (61) 2018 72/M recurrent mass of the anterior abdominal wall CD34+, CD99+, vimentin+,
Jung and Bae (62) 2019 57/M No CD34+, STAT 6+
Suzuki et al. (63) 2019 45/F abdominal pain CD34+, bcl-2+, STAT6+,
CD99+, c-kit-, S-100-, desmin-
EMA: epithelial membrane antigen; ER: estrogen receptor;  F: female;  HIC: immunohistochemistry  HPC: hemangiopericytoma; 
LCA: leukocyte common antigen; M: male; NA: not available;  PR: progesterone receptor; SFT: solitary fibrous tumor; 
SMA: smooth muscle actin
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Table 1 - Main demographic, clinical and immunohistochemical findings of SFT of the greater omentum 
as depicted in the current literature (continuation)
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often attributable to a mass-compression effect on the
surrounding anatomic structures. In addition, three
cases manifested with haemoperitoneum (26,28,39),
while five lesions mimicked an ovarian tumor
(16,27,54,57,60).
The imaging techniques most frequently employed
were roentgenograms and CECT. SFT tend to be well-
defined, ovoid, and heterogeneously enhanced lesions
in imaging. CECT and magnetic resonance imaging
(MRI) appearance of abdominal and pelvic SFTs 
commonly consists in large, well-defined, ovoid, 
moderate enhancing masses, with heterogeneous CT
attenuation or MRI signal intensity due to variable
degrees of necrosis, haemorrhage and/or cystic 
evolution (65,66). Such non-specific imaging features
lead to a wide spectrum of differential diagnoses to
consider, including mainly other highly vascularized
and/or fibrous-rich tumours such as leiomyosarcoma,
neurogenic tumour, lymphoma, malignant fibrous 
histocytoma and mesothelioma. (65). The presence of a
prominent vascular pedicle, although non-specific, has
been described as a useful diagnostic feature of SFTs,
and has been reported in 35% to 100% of the cases
(67). 
Histologic features that define SFT as a malignant
neoplasm have been proposed, but no unanimous 
criteria have been established. Zong et al. (45) suggested
a risk assessment algorithm to predict SFT behaviour
based on tumor size, mitotic activity, cellularity and
pleomorphism. It distinguishes SFTs in very low, low,
intermediate and high risk tumors. Furthermore, in a
series of 110 cases, Demicco et al. proposed a risk 
stratification model for metastasis and death from 
disease, identifying three prognostic groups: low, 
intermediate and high risk patients (68). Nevertheless,
no comprehensive studies have been performed to
accurately determine the neoplastic aggressiveness of
SFT so far. Furthermore, less is known about the 
genetic ad molecular events responsible for the patho-
genesis of SFT, and how this may relate to clinically
determined risk factors. In addition, the predicitve
value of the few immunohistochemical or molecular
biomarkers (including p53, telomerase activity, cycle
expression, and Ki67) that have been suggested to 
have prognostic significance in SFT, remains yet to be
clarified.
On gross pathologic examination, SFTs were 
commonly solid masses, well-circumscribed, encap-
sulated, and non-infiltrating. Most cases showed 
prominent vascularity with numerous small and 
medium size vessels, often adopting focally a hemangio-
pericytic growth pattern. Typical histological features 
of SFTs consist in a combination of hypercellular and
collagenous areas; in some cases, it can be difficult to
evaluate malignancy only according to morphology
and immunohistochemical (IHC) features may be 
useful like positivity of CD34, bcl-2 and STAT6 which
are the most important markers for diagnosis, 
especially in differentiating SFTs from gastro-
intestinal stromal tumors (GISTS) (53). In particular,
STAT6 has recently emerged as a sensitive and 
specific marker, which identifies the NAB2-STAT6
fusion product (69). Occasionally, SFTs are positive
for epithelial membrane antigen (EMA), smooth
muscle actin (SMA), and negative for cytokeratin,
S100, and desmin. In our review, positivity for
vimentin was found in all the 9 cases reporting on
IHC (table 1). CD34 and bcl-2 were the immuno-
stainings most frequently used (30 and 11 cases,
respectively); the former was positive in 100%, and
the latter in 91% of the examined cases (table 1).
Frequent immunostaining for CD 99 was detected
(90%), as well as negativity for desmin (10 of the 11
reported cases) and smooth muscle actin (SMA).
The ideal therapy for malignant SFTs is uncertain,
and the assessment of the most effective clinical 
management remains to be established. Information
about the employed treatments and the prognosis was
available in 57 cases. In all these cases surgery was the
treatment of choice, with an associated complete
omentectomy perfomed in nine (16%) cases. Three
cases required an extended resection, with the exeresis
of bilateral adnexa (two cases), as well as uterus,
appendix and perirectal metastases. Considering the
favourable oncological outcomes of SFT, radiotherapy is
generally not indicated when surgical excision has
resulted in negative margins, and it is usually reserved
in cases with incomplete resection or recurrence.
Chemotherapy or targeted therapies with tyrosin
kinase inhibitors (TKIs) may be recommended especially
in unresectable cases, since half of these tumours is 
positive for cKIT TKIs (70). However, it is difficult to 
identify the most effective chemotherapy regimen for
advanced SFTs on the basis of the current evidence.
Cytotoxic doxorubicin based, gemcitabine based, and
paclitaxel based schemes are used for patients with
locally advanced, recurrent, or metastatic disease, but
results have been variable, often with low response
rates (71). Several novel targeted strategies, like temo-
zolomide bevacizumab combination therapy, sunitinib,
sorafenib and pazopanib have recently shown 
promising results (72), but further studies are needed
to validate their routine use. 
Also the prognosis of patients affected by omental
Surgery, Gastroenterology and Oncology, 25 (3), 2020 161
Solitary Fibrous Tumor of the Omentum: Presentation of a Case and Literature Review
SFT remains difficult to establish. In general, most of the
patients with extrapleural disease show a benign 
clinical course after complete surgical resection. The
overall median 5- and 10-year survival rates after 
surgical resection are 59% to 100% and 40% to 89%,
respectively (73). Nevertheless, some omental SFTs
showed aggressive malignant behavior resulting in
recurrence or metastasis, even many years after the
surgical removal. Ten (18%) patients presented distant
metastases with a median time between the start of
frontline treatment and first recurrence of 25 months
(range 3–52). Globally, six (10%) patients died because
of the disease, three (5%) were alive with disease, and
thirty (53%) were free of disease in the cases reviewed.  
CONCLUSIONS
In conclusion, we came across a rare case of giant
SFT originating from greater omentum. Imaging, 
especially CT or MRI, are useful for the detection and
anatomic evaluation of these tumors, but only surgery
with subsequent pathological examination and immuno-
histochemical tests can provide a certain diagnosis of
SFT. Surgery, with or without radiation and chemo-
therapy, should be considered for treatment on the
basis of the dimensions and extension of the lesions,
with a long-term follow-up in order to early detect local
recurrences and distant metastases.
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